A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant
depression (TRD).